After striking a Most Favored Nation deal with the White House in January, Johnson & Johnson will now offer Xarelto at 68% ...

With Phase 3 data in hand, Intellia Therapeutics is seeking approval for its in vivo CRISPR gene editing therapy for ...

While tovecimig met the main goal of progression-free survival in a Phase 2/3 trial, it did not improve overall survival.

As cell and gene therapy leaders gathered in Maryland to discuss accelerating clinical trials in children, one “cutting edge” ...

FDA inspectors warned UCSF radiopharmaceutical facility that losing environmental control could pose a serious hazard to ...

Trained biostatisticians play a central role in clinical science and public health. Brown’s online master’s in biostatistics ...

Pfizer’s decision to cut its early-stage cancer asset was due to “strategic business reasons” and not driven by safety or ...

While the FDA did not announce the recipient names of the Commissioner’s National Priority Vouchers, the agency’s ...

Eli Lilly and Rigel Pharmaceuticals partnered in February 2021 to advance a pair of RIPK1 blockers, but the pharma in October ...

The Durham plant will manufacture immunology, neuroscience and oncology drugs once AbbVie finishes construction in 2028.

Women and nonwhite racial/ethnic groups are still earning less in the life sciences. An industry consultant discusses the pay ...

Of the 17 companies that were implored by the White House last July to apply Most Favored Nation pricing to their drugs, ...